Viking Therapeutics (VKTX) to Release Earnings on Wednesday

Viking Therapeutics (NASDAQ:VKTX) is expected to be announcing its Q1 2026 results after the market closes on Wednesday, April 22nd. Analysts expect the company to announce earnings of ($1.01) per share for the quarter. Interested persons may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Wednesday, April 29, 2026 at 4:30 PM ET.

Viking Therapeutics (NASDAQ:VKTX) last posted its earnings results on Wednesday, February 11th. The biotechnology company reported ($1.38) EPS for the quarter, missing the consensus estimate of ($0.89) by ($0.49). During the same period last year, the business posted ($0.32) EPS. On average, analysts expect Viking Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Viking Therapeutics Price Performance

Viking Therapeutics stock opened at $35.20 on Monday. The stock’s 50 day moving average is $33.02 and its 200 day moving average is $33.96. Viking Therapeutics has a one year low of $22.96 and a one year high of $43.15. The firm has a market cap of $4.08 billion, a P/E ratio of -11.07 and a beta of 0.83.

Insider Transactions at Viking Therapeutics

In other news, insider Neil William Aubuchon purchased 4,475 shares of the stock in a transaction dated Tuesday, March 10th. The shares were purchased at an average cost of $33.50 per share, with a total value of $149,912.50. Following the completion of the acquisition, the insider owned 4,475 shares in the company, valued at $149,912.50. This represents a ∞ increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Company insiders own 5.30% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of VKTX. Quattro Advisors LLC bought a new stake in shares of Viking Therapeutics during the 4th quarter worth $37,000. Northwestern Mutual Wealth Management Co. increased its stake in Viking Therapeutics by 29.5% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 2,109 shares of the biotechnology company’s stock valued at $56,000 after acquiring an additional 481 shares during the last quarter. Banque Cantonale Vaudoise increased its stake in Viking Therapeutics by 16.7% in the third quarter. Banque Cantonale Vaudoise now owns 3,752 shares of the biotechnology company’s stock valued at $98,000 after acquiring an additional 536 shares during the last quarter. Parallel Advisors LLC raised its holdings in shares of Viking Therapeutics by 167.0% during the 3rd quarter. Parallel Advisors LLC now owns 4,854 shares of the biotechnology company’s stock valued at $128,000 after buying an additional 3,036 shares in the last quarter. Finally, Utah Retirement Systems bought a new position in Viking Therapeutics during the fourth quarter valued at approximately $201,000. Hedge funds and other institutional investors own 76.03% of the company’s stock.

Analyst Ratings Changes

Several brokerages have issued reports on VKTX. Morgan Stanley reiterated an “overweight” rating and issued a $99.00 price target on shares of Viking Therapeutics in a report on Thursday, February 12th. Weiss Ratings restated a “sell (d-)” rating on shares of Viking Therapeutics in a research note on Wednesday, January 21st. HC Wainwright reaffirmed a “buy” rating and set a $102.00 price target on shares of Viking Therapeutics in a research report on Monday, March 23rd. Wolfe Research started coverage on Viking Therapeutics in a report on Thursday, March 26th. They set a “peer perform” rating on the stock. Finally, Zacks Research upgraded Viking Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Wednesday, February 18th. Four research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $94.22.

Viking Therapeutics Company Profile

Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders. Headquartered in San Diego, California, the company’s pipeline leverages small-molecule approaches to target hormone signaling pathways implicated in conditions such as non‐alcoholic steatohepatitis (NASH), dyslipidemia, type 2 diabetes and muscle wasting disorders.

The company’s lead programs include VK2809, a thyroid hormone receptor‐beta agonist designed to reduce liver fat and improve lipid profiles in patients with NASH and dyslipidemia, and VK5211, a selective androgen receptor modulator (SARM) aimed at enhancing muscle mass and function in individuals with muscle wasting conditions.